AstraZeneca PLC (NASDAQ:AZN) Announces Semi-annual Dividend of $0.51

Key Points

• AstraZeneca PLC declared a semi-annual dividend of $0.51, with a yield of 2%, payable on September 8th for investors of record on August 8th.
• The company reported a quarterly earnings per share (EPS) of $1.09, meeting analysts' expectations, with revenue up 16.1% year-over-year.
• AstraZeneca's market capitalization stands at $237.53 billion, with analysts providing a consensus price target of $89.00 and a "Moderate Buy" rating.

AstraZeneca PLC (NASDAQ:AZN - Get Free Report) announced a semi-annual dividend on Tuesday, July 29th, Wall Street Journal reports. Stockholders of record on Friday, August 8th will be paid a dividend of 0.505 per share on Monday, September 8th. This represents a dividend yield of 200.0%. The ex-dividend date of this dividend is Friday, August 8th.

AstraZeneca has a dividend payout ratio of 41.3% indicating that its dividend is sufficiently covered by earnings. Analysts expect AstraZeneca to earn $5.00 per share next year, which means the company should continue to be able to cover its $2.10 annual dividend with an expected future payout ratio of 42.0%.

AstraZeneca Stock Performance

AstraZeneca stock traded up $0.67 during trading hours on Friday, hitting $73.76. The company had a trading volume of 7,140,695 shares, compared to its average volume of 5,404,447. The firm has a market cap of $228.74 billion, a PE ratio of 27.71, a PEG ratio of 1.41 and a beta of 0.37. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.70. AstraZeneca has a one year low of $61.24 and a one year high of $87.68. The firm has a 50-day moving average of $71.48 and a 200 day moving average of $71.31.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $14.46 billion for the quarter, compared to analysts' expectations of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The business's revenue was up 16.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.24 EPS. On average, sell-side analysts expect that AstraZeneca will post 4.51 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.